LABORATORY AND CLINICAL EVALUATION OF CEFOTAXIME

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement1; pp. 379 - 386
• Main Authors: KURIMURA, OSAMU, SASAKI, HIDEO, TAMAKI, KAZUE, MURAI, TOMOYA, NOZAKI, KIMITOSHI, MATSUKI, SATORU, DOI, HIDEYUKI, YAGUCHI, HIROMI, YOKOTA, KAZUKO, SHIMONAKA, AKIKO, MORIOKA, YUSUKE
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 01.01.1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement1_379

The antibacterial activity of cefotaxime in vitro against gram-positive microorganisms was less than that of cefazolin and cefuroxime, and was comparable to that of cefmetazole. On the other hand, the activity of cefotaxime against Haemophilus, Proteus, Klebsiella, Shigella, and Salmonella was very strong, and against Enterobacter, Citrobacter, and Serratia cefotaxime showed lower MICs than those of the other cephalosporins. In clinical trials, cefotaxime's efficacy was good in 3 out of 4 patients with RTI. The antibiotic showed good results in 1 case and excellent results in 3 cases out of 8 cases of UTI The 4 UTI cases that did not respond to treatment were complicated by prostatic hypertrophy. Excellent results were obtained in 1 case each of pneumococcal meningitis, α-streptococcal subacute bacterial endocarditis, and a healthy typhoid carrier; good results were obtained in 1 case of fever of unknown origin. An adverse reaction was observed in a patient with chronic panbronchiolitis, who suffered from dyspnea during drip infusion of cefotaxime.